Interleukin-12 (IL-12) is a 70-kDa heterodimeric cytokine composed of a 35-kDa subunit (p35) and a 40-kDa subunit (p40). We have demonstrated previously that intratumoral delivery of a recombinant adenoviral vector expressing the mouse IL-12 gene significantly prolongs the survival time of mice with metastatic colon carcinoma in the liver. We now report the molecular cloning of cDNA for both subunits of human IL-12 (hIL-12) in a recombinant adenoviral vector in which the p40 and p35 subunits are linked and coexpressed using the encephalomyocarditis virus internal ribosome entry site. The recombinant adenoviral vector was used to transduce human tumor cell lines, and the presence of hIL-12 in the conditioned media was illustrated by enzyme-linked immunosorbent assay. The biological activity of hIL-12 in the conditioned media was also demonstrated in vitro through its ability to induce interferon-␥ production from peripheral blood mononuclear cells (PBMCs), to stimulate PBMC proliferation, and to enhance natural killer activity from normal human PBMCs to lyse natural killer-sensitive K562 target cells. The results of these studies support the application of this recombinant adenoviral vector construct as an efficient gene delivery vehicle in phase I/II clinical studies of hIL-12 gene therapy for cancer.
I
nterleukin-12 (IL-12) is a heterodimeric cytokine composed of two disulfide-linked subunits of 35 and 40 kDa. [1] [2] [3] This protein, previously called cytotoxic lymphocyte maturation factor 2 or natural killer (NK) cell stimulatory factor, 1 is predominantly secreted by peripheral blood antigen-presenting cells such as macrophages and dendritic cells. It has multiple biological effects on T cells and NK cells, including the stimulation of cytotoxic activity, proliferation, promotion of T helper 1 cell development, and interferon-␥ (IFN-␥) production, leading to cellular-mediated immunity. 4 -9 Systemic administration of recombinant in animals has shown that this cytokine can inhibit tumor growth and reduce metastases that result in prolonged survival. 10, 11 However, its clinical applications were limited by systemic toxicity at the effective doses. 12 Local delivery of IL-12 to the tumor site could potentially reduce the adverse effects associated with systemic delivery. The cDNAs encoding the p35 and p40 subunits of IL-12 for both mice and humans have been cloned. [13] [14] [15] Several studies have shown that local delivery of IL-12-expressing fibroblasts inhibits tumor growth and leads to the development of an antitumor immune response. 16 -18 Adenoviral vectors are capable of achieving high levels of gene transfer to various target cells in vivo. This capacity has made adenoviral vectors excellent vehicles for gene therapy in various tumor models in laboratory animals and in clinical applications. Previous results have suggested that replication-deficient adenovirus (Ad) vectors expressing mouse IL-12 are effective in the treatment of cancer. 19 -22 Here, we report the construction and characterization of a recombinant adenoviral vector expressing the functional heterodimeric human IL-12 (hIL-12) cytokine. The vector can be used to transduce human tumor cells to secret immunoreactive hIL-12 into the conditioned media. The virally derived hIL-12 protein also has the same biological activities as rhIL-12 in vitro.
MATERIALS AND METHODS

Cell lines and reagents
The NC-37 cell line (human lymphoblastoid cells, CCL-214; American Type Culture Collection (ATCC), Manassas, Va) and the HeLa cell line (human cervix cell line, CCL-2; ATCC) were grown in RPMI 1640 with 10% fetal bovine sera (FBS). The 293 cell line 23 (adenoviral E1-transformed human embryonic kidney cells) was maintained in Dulbecco's modified Eagle's medium plus 10% FBS. Lovo cells, derived from human colon adenocarcinoma, were grown in Ham's F-12 medium with 20% FBS. All culture medium was supplemented with 2 mM glutamine, 100 U/mL streptomycin, and 100 g/mL penicillin.
Peripheral Cloning of p40 and p35 cDNAs of hIL-12 NC-37 cells was stimulated with 10 ng of phorbol 12-myristate 13-acetate and 20 ng of calcium ionophore A23187 for 48 hours. The total RNA was extracted and was quantitated by spectrophotometry. Reverse transcriptase-polymerase chain reaction (PCR) was performed to amplify the hIL-12 p40 and p35 cDNAs for subsequent cloning purpose. For p40, the sense primer (GGGGTACCATGTGTCACCAGCAGTTGGT) corresponded to the N-terminal nucleotides (14-33 base pairs (bp) of p40 cDNA preceded by a KpnI site). The antisense primer (GGGGTACCATTAATCTAACTGCAGGGCACAGATG) corresponded to the C-terminal nucleotides (1000-981 bp of p40 cDNA followed by a KpnI site). 24 For p35, the sense primer (CCCACATGTGGCCCCCTGGGTCAGC) corresponded to the N-terminal nucleotides (102-121 bp of p35 cDNA preceded by an AflIII site); the antisense primer (AAGGAAAAAAGCGGC-CGCTTAGGAAGCATTCAGATAGC) corresponded to the C-terminal nucleotides (863-844 bp of p35 cDNA plus a NotI site). 24 The PCR product for hIL-12 p40 was subcloned into the KpnI site of the pBluescript plasmid. The p35 cDNA was subcloned into the NcoI and NotI sites of the pCITE-2a ϩ plasmid (Novagen, Madison, Wis), where the ATG in the NcoI site following the internal ribosome entry site (IRES) sequence from encephalomyocarditis virus was used as the initiation codon of p35. The resulting recombinant pCITE plasmid could be digested by VspI and NotI to generate the IRES-p35 fragment. The cloned DNA sequences of p40 and p35 were determined in their entireties.
Construction of a recombinant adenoviral vector expressing hIL-12
To generate pADV.RSV-p40 DNA, hIL-12 p40 cDNA was released by KpnI from pBluescript and subcloned into the KpnI site of the adenoviral vector pADV.RSV-bpA that had been constructed by insertion of a DNA fragment containing Rous sarcoma virus (RSV) promoter, a polylinker sequence, and the bovine growth hormone (BGH) poly(A) signal into the pX-CJL0.1 vector. 25 Plasmid pXCJL0.1 contains adenoviral genomic fragments of 1-455 bp and 3328 -5788 bp in pBR322. 26 The pADV.RSV-hIL-12 plasmid was constructed by inserting the IRES-p35 fragment into the EcoRV and NotI sites of the pADV.RSV-p40 DNA. The recombinant Ad ADV.RSV-hIL-12 was produced by cotransfection of the adenoviral transfer vector pADV.RSV-hIL-12 and pBHG10 27 into 293 cells using the calcium phosphate precipitation method. Single plaques were picked and purified by double CsCl gradient ultracentrifugation as described previously. 28 Virus particle titer was determined by optical absorbance at 260 nm, and infectious unit titer (plaque-forming units/mL) was quantitated by plaque assay using 293 cells.
hIL-12 ELISA
The two human tumor cell lines, HeLa (cervical carcinoma cells) and Lovo (colon carcinoma cells), were transduced with the ADV.RSV-hIL-12 or DL312 control vectors at a multiplicity of infection (MOI) of 30. The supernatants were harvested 48 hours postinfection. The hIL-12 concentrations in the supernatants were determined by ELISA for p70 heterodimer (ELISA kit from Endogen).
IFN-␥ induction assay
Human peripheral blood was obtained from healthy donors. PBMCs were separated on a Ficoll-Hypaque density gradient. A total of 4 ϫ 10 6 fresh PBMCs were plated in a 24-well plate at a concentration of 2 ϫ 10 6 cells/mL. The PBMCs were incubated with serial dilutions of culture supernatant from HeLa cells transduced with ADV.RSV-hIL-12 or with those supernatants from control vector DL312-transduced or mocktransduced cells. The supernatants from the treated PBMCs were harvested after 48 hours and tested for the presence of IFN-␥ in the media by ELISA (Endogen). rhIL-12 (20 ng/mL) was used as a positive control.
PBMC proliferation assay
PBMCs were prepared as described above. PBMCs were seeded in a 96-well plate at a density of 1 ϫ 10 5 cells/well in a final volume of 100 L and incubated with the 2-fold-diluted supernatants from HeLa cells transduced with ADV.RSVhIL-12 or DL312 or with supernatant from mock-transduced HeLa cells. PBMCs were incubated with the conditioned media containing different concentrations of rhIL-12 to establish a positive control. Cells were incubated for 48 hours at 37°C and subsequently pulsed for 8 hours with 1 Ci of [ 3 H]thymidine per well and harvested. [ 3 H]thymidine incorporation was determined using a beta scintillation counter (Wallac, Gaithersburg, Md). Samples were set up in triplicate.
NK activity assay
To further characterize the biological activity of the hIL-12 produced by ADV.RSV-hIL-12-transduced cells, its ability to enhance NK killing activity was determined in vitro. Freshly isolated PBMCs from the human peripheral blood of a normal volunteer donor were cultured for 1 hour on plastic to deplete monocytes or were used as effector cells without depletion. Next, the PBMCs were incubated in the presence of the test supernatants from cells transduced with ADV.RSV-hIL-12. The supernatants from DL312-transduced cells and rhIL-12 (1 ng/mL) were used as controls. After a 24-hour incubation, the cells were harvested, washed, and used as effector cells. 
RESULTS
Construction of ADV.RSV-hIL-12
The sequence of full-length p40 and p35 cDNAs of hIL-12 has been reported previously. 24 Using reverse transcriptase-PCR, we amplified and cloned p40 and p35 cDNAs from phorbol 12-myristate 13-acetate and calcium ionophore-activated human NC-37 B lymphoblastoid cells obtained from ATCC. The cDNAs were sequenced in their entireties, and the respective cDNAs with correct sequences were linked with the IRES sequence obtained from the pCITE-2a ϩ vector. The bicistronic pADV.RSV-hIL-12 plasmid DNA was constructed by inserting the p40-IRES-p35 fragment into the KpnI and NotI sites of pADV.RSV-bpA, a plasmid containing part of the adenoviral genome, the RSV long-terminal repeat promoter, and the BGH poly(A) tail. Cells transfected with this plasmid expressed a high level of hIL-12 in the culture media (data not shown). Recombinant Ad (ADV.RSV-hIL-12) was produced by cotransfecting pADV.RSV-hIL-12 with pBHG10 into transformed kidney cells (293) using the calcium phosphate method. The replication-defective Ad produced by homologous recombination was isolated from a single plaque and expanded in 293 cells. The expression cassette of hIL-12 inserted into the E1 region of the recombinant adenoviral vector is shown in Figure 1 . The vector was prepared in large scale and purified using double CsCl gradient ultracentrifugation.
Expression of hIL-12 in ADV.RSV-hIL-12-transduced cells
To assess the expression of hIL-12, two human tumor cell lines were transduced with ADV.RSV-hIL-12 or control vector ADV-DL312 at an MOI of 30. The hIL-12 levels from the supernatants of the transduced cells were measured using an ELISA kit specific for the heterodimer p70. At 48 hours posttransduction, hIL-12 production was 32 ng/10 6 cells in a transduced human colon carcinoma cell line (Lovo) and 80 ng/10 6 cells in a transduced human cervical carcinoma cell line (HeLa). There was negligible hIL-12 in the supernatants from control vector-transduced cells or mock-transduced tumor cells (Fig 2) . The P value is .001 for ADV.RSV-hIL-12-versus DL312-transduced Lovo cells by Student's t test.
Functional characterization of hIL-12 produced from ADV.RSV-hIL-12-transduced cells
The biological activities of the hIL-12 protein expressed by the transduced cells were measured by induction of IFN-␥, stimulation of PBMC proliferation, and enhancement of NK activity in normal human PBMCs. Significant biological activity was detected in the supernatants of the ADV.RSV-hIL-12-transduced cells. There was a dose-dependent induction of IFN-␥; at an hIL-12 concentration of 8 ng/mL, the IFN-␥ induction activity approached that of the purified rIL-12 protein at 20 ng/mL. The IFN-␥ production from the mock-transduced cells as well as control vector-transduced cells was markedly reduced (Fig 3) . The data using the logarithm (base e) transformation were examined by Student's t test. The result is significant, P ϭ .023, between ADV.RSV-hIL-12 versus DL312. The effect of the hIL-12 produced from ADV.RSVhIL-12 on the proliferation of PBMCs was evaluated. As shown in Figure 4 , [ 3 H]thymidine incorporation was significantly increased in the PBMCs stimulated with the supernatants from the ADV.RSV-hIL-12-transduced cells at the concentrations tested; nevertheless, the supernatants from the DL312-or mock-transduced cells had a less significant effect on enhancing the proliferation of PBMCs (Fig 4) . The group differences between ADV.hIL-12 and DL312 were examined by repeated measures analysis of variance (ANOVA), P ϭ .006. The data were transformed using the logarithm (base e) transformation before proceeding with the analysis. The functionality of the virally produced hIL-12 was further character- 
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ized by its NK enhancement activity. After the human PBMCs with or without depletion of adherent monocytes were stimulated with the supernatant from the ADV.RSV-hIL-12-transduced cells, the cytolytic activity against K562, an NK-sensitive cell line, was significantly enhanced compared with the supernatant from DL312-transduced cells (P ϭ .0002 by repeated measures ANOVA) (Fig 5) . These activities were comparable with the stimulatory effects of rhL-12.
DISCUSSION
IL-12, a cytokine produced by activated monocytemacrophages and dendritic cells, has multiple immunological activities. It induces IFN-␥ production by both resting and activated NK cells, CD4 ϩ T cells, and CD8 ϩ T cells. It also enhances the lytic activities of NK cells, stimulates the differentiation of T helper 1 cells, and elevates specific cytotoxic T-lymphocyte responses. Recent studies have demonstrated the antitumor effects of IL-12 against a variety of tumor models in mice, including B16 melanoma, M5076 reticulum cell sarcoma, Lewis lung carcinoma, Renca renal cell adenocarcinoma, and MCA26 colon carcinoma; specifically, it was reported that the treatment of IL-12 by itself was also effective on a major histocompatibility complex-negative metastatic melanoma. 29 Tumor regression and/or prolonged survival of treated animals has been documented in murine models using systemic or peritumoral administration of IL-12.
10,13 Studies in mice have also suggested that the local delivery of IL-12 to tumors is more efficient than systemic administration. 10 In addition to its ability to enhance an immune response, Voest et al 30 reported that IL-12 contributed to the suppression of angiogenesis in mice, which may have antitumoral activity by itself. All of these biological properties make IL-12 a particularly valuable cytokine for cancer therapy. These beneficial effects of IL-12 notwithstanding, a high dose IL-12 administrated systemically is associated with severe toxicity in preclinical studies, [31] [32] [33] and two patients died in clinical trials. 12 The systemic toxicity of IL-12 can potentially be avoided if the powerful cytokine is produced locally in situ. This can be achieved by either cell-based or gene-based strategies for IL-12 gene transfer and expression in vivo. The implantation of engineered tumor cells or fibroblasts expressing mouse IL-12 into murine tumors can cause a rejection of established tumors and can elicit a systemic antitumor immune reaction specific for the tumor type at a distant site. 16 -18 Lotze et al 34 have already initiated a phase I/II clinical trial of hIL-12 gene therapy of several different tumors by direct injection of tumors with genetically engineered autologous fibroblasts. The results showed evidence of a tumor response in patients with advanced cancer. In addition, Sun et al 35 reported in another recent clinical phase I study that the patients with metastatic melanoma in an advanced stage could achieve a modulation of the immune response after vaccination with hIL-12 genemodified autologous melanoma cells. Alternatively, the IL-12 gene can be directly delivered into the tumor through adenoviral-mediated gene transfer. In an orthotopic model of hepatic metastasis of colon carcinoma and a subcutaneous model of metastatic breast carcinoma, we and others have demonstrated that the intratumoral administration of recombinant adenoviral vectors expressing mouse IL-12 was efficacious in causing tumor destruction and in significantly prolonging the survival of the tumor-bearing animals. 20, 21 Considering these preclinical results, intratumoral delivery of recombinant adenoviral vectors expressing hIL-12 may be an excellent strategy to achieve its therapeutic potential while avoiding the toxicity associated with systemic delivery of rIL-12.
In this study, we reported the cloning of the p40 and p35 cDNAs of hIL-12 from human NC-37 B lymphoblastoid cells. These cDNAs contain the complete and correct coding sequences for the two subunits of hIL-12, as determined by DNA sequencing (data not shown). Because IL-12 is a heterodimeric cytokine and the synthesis of bioactive IL-12 requires the coexpression of both subunits, we used the IRES sequence from encephalomyocarditis virus to link the two cDNAs to produce a bicistronic gene in the pADV.RSV-hIL-12 plasmid. Our results demonstrate that the hIL-12 produced by cells transduced with the ADV.RSV-hIL-12 is functional, including its ability to induce IFN-␥ produc- tion, to stimulate proliferation, and to enhance the NK activity from normal human PBMCs. The specific activity of this hIL-12 is comparable with that of purified rhIL-12. Use of the IRES sequence to link and coexpress the two subunits has also been achieved in a retroviral vector, and it expressed similar levels of both hIL-12 subunits (p35 and p40) as evidenced by ELISA. 36 The recombinant retroviral vectors are limited by their ability to transduce only dividing cells and by relatively low viral titers. Thus, retroviral vectors have been used mostly in ex vivo cell-based gene therapy for cancer. Recently, Zhang et al 37 used a Semliki Forest virus (SFV) vector to express hIL-12. Recombinant SFV vectors are produced by the cotransfection of vector RNA and nonpackageable SFV-help2 RNA molecules into cultured cells and are limited by a relatively low viral titer and yield. This recombinant SFV vector also requires a preactivation step before cellular transduction. Alternatively, the recombinant adenoviral vectors can be readily produced at high titer and high yield by viral passaging in complementing cells. The recombinant adenoviral vectors can efficiently transduce both dividing and nondividing cells in vitro and in vivo. Although it is known to result in only short-term transgene expression in immunocompetent animals due to immunological rejection of the transduced cells after 1-2 weeks, this limitation does not apply to cancer gene therapy if the goal is to destroy the tumor cells within that time frame.
Combining the properties of recombinant adenoviral vectors with the therapeutic potential of IL-12, the adenoviral vector expressing hIL-12 will be readily applicable in future phase I/II clinical trials of gene therapy for cancer. In addition, it can potentially be used in combination with other genes and reagents such as other cytokines to achieve maximal therapeutic effects. 38 -41 
